T-DM1 is currently approved only for advanced HER2-positive breast cancer previously treated with trastuzumab, but a defined RAB5A threshold-biomarker holds promise also for patient stratification at earlier stages of this disease29, in addition to other indications, such as gastric cancer23. This evidence concerns the gene ERBB2 and breast cancer.